Clinical Research

Obicetrapib linked to substantial reductions in LDL cholesterol for high-risk heart patients

Researchers shared new studies on the highly selective CETP inhibitor in The New England Journal of Medicine and The Lancet.

Thumbnail

MRI data show how sleep apnea damages the brain

Obstructive sleep apnea during the rapid-eye-movement stage of sleep could be causing damage to parts of the brain that control memory and cognition.

heart ice cool cold freezing frozen

Cardiologists are first in world to use new cooling device to terminate AFib during surgery

Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of the patient's heart as soon as AFib starts to develop may represent a new way to stop the problem in its tracks. 

Dan Budoff explains use of CCTA to track coronary disease plaque progression

CCTA shows colchicine's impact on atherosclerosis progression

Matthew Budoff, MD, detailed new data highlighting CCTA's value when it comes to tracking the progression of coronary atherosclerosis.

MRI biomarkers could signal early onset of Parkinson's.

Experts identify MRI biomarkers that could signal the early onset of Parkinson's

Using one of the most powerful MRI scanners to date, researchers believe they have identified subtle neural changes in the brain that precede Parkinson’s disease. 

PET imaging reveals long-term heart and lung damage from COVID-19

New data highlight the long-lasting effects of the coronavirus, revealing changes that are not detectable by standard medical assessments. 

Cardiologist heart

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 

tirzepatide injections Zepbound Eli Lilly

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.